Key facts
- This page summarizes Vijay Patel's Form 3 filing for Kintara Therapeutics, Inc. (HURA).
- 0 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 22 Oct 2024, 20:50.
Vijay Patel - 18 Oct 2024 Form 3 Insider Report for Kintara Therapeutics, Inc. (HURA)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- HURA
- Reported as of
- 18 Oct 2024
- Net transaction value
- $0
- Reporting owner signature
- /s/ Dan Dearborn as Power of Attorney for Vijay Patel
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Vijay Patel filed Form 3 for Kintara Therapeutics, Inc. (HURA) on 22 Oct 2024.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
KTRA
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 7,999,557
- Date
- 18 Oct 2024
- Ownership
- See Footnote
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
KTRA
holding
Derivative
Warrants
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Oct 2024
- Ownership
- See Footnote
- Underlying class
- Common Stock
- Underlying amount
- 3,049,432
- Exercise price
- $3.69
- Footnotes
- F1, F2
KTRA
holding
Derivative
Warrants
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Oct 2024
- Ownership
- See Footnote
- Underlying class
- Common Stock
- Underlying amount
- 1,315,441
- Exercise price
- $5.70
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Securities issued upon closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of April 2, 2024 (the "Merger Agreement"), among the Issuer (fka "Kintara Therapeutics, Inc."), Kayak Mergeco, Inc., a Delaware corporation and wholly owned subsidiary of Issuer ("Merger Sub"), and TuHURA Biosciences, Inc., a Delaware corporation ("Private TuHURA"). Under the terms of the Merger Agreement, on October 18, 2024, Merger Sub merged with and into Private TuHURA (the "Merger") with Private TuHURA surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, securities of Private TuHURA were converted into the right to receive securities of the Issuer as set forth in the Merger Agreement. The Issuer subsequently changed its name to "TuHURA Biosciences, Inc."
Footnote F2
The shares are owned by K&V Investment One, LLC, an entity over which the reporting person has beneficial ownership through his position as sole manager.
SEC remarks
See Exhibit 24 - Power of Attorney.